Recognize the problem –
catheter-related bloodstream infections (CRBSIs) are a hospital-wide challenge.

High Incidence

- Although CVCs are implicated in the majority of CRBSI, non-CVC devices account for 30% of total CRBSI
- Of the 250,000 CVC-related bloodstream infections reported annually, 68% occurred outside the ICU

CRBSI’s impact on patient recovery and hospital costs

BIOPATCH® is the ONLY protective disk with an FDA cleared indication PROVEN to reduce the incidence of CRBSIs, local infections and skin colonization in patients with central venous and arterial catheters.¹
Recognize the problem – catheter-related bloodstream infections (CRBSIs) are a hospital-wide challenge.

CRBSIs...The Scope

High Incidence
- Although CVCs are implicated in the majority of CRBSI, non-CVC devices account for 30% of total CRBSI.
- Of the 250,000 CVC-related bloodstream infections reported annually, 68% occurred outside the ICU.

CRBSI's impact on patient recovery and hospital costs
- Incremental cost per CRBSI episode ranges from $25,000 to $56,000.
- Hospitals absorb majority of costs.
- US hospitals incur as much as $2.3 billion per year as a result of CRBSIs.

The Need to Take Action - ZERO is the Goal

<table>
<thead>
<tr>
<th>Organization</th>
<th>Statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joint Commission</td>
<td>Nation Patient Safety Goal #7.4.1 - Implement evidenced-based guidelines to prevent central line associated bloodstream infections by January 1, 2010.</td>
</tr>
<tr>
<td>CDC</td>
<td>2011 CDC Guidelines for Prevention of Intravascular Catheter-Related Infections strongly recommends the use of a CHG impregnated sponge dressing Category 1B.</td>
</tr>
<tr>
<td>SHEA/IDSA</td>
<td>Five leading healthcare stakeholders (SHEA, IDSA, AHA, APIC, and Joint Commission) have worked together to develop strategies to prevent six of the most important healthcare associated infections (HAIs), including central line associated bloodstream infections.</td>
</tr>
<tr>
<td>APIC</td>
<td>&quot;Targeting Zero&quot; Initiative - &quot;While not all infections are preventable, working toward zero should be the goal.&quot;</td>
</tr>
</tbody>
</table>

CRBSIs...The Scope

Annual Bloodstream Infections (n = 357,000)5

CRBSIs...The Scope

Annual Central Venous CRBSIs (n = 250,000)5

CRBSIs...The Scope

CRBSIs...The Scope

The Need to Take Action - ZERO is the Goal

<table>
<thead>
<tr>
<th>Organization</th>
<th>Statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joint Commission</td>
<td>Nation Patient Safety Goal #7.4.1 - Implement evidenced-based guidelines to prevent central line associated bloodstream infections by January 1, 2010.</td>
</tr>
<tr>
<td>CDC</td>
<td>2011 CDC Guidelines for Prevention of Intravascular Catheter-Related Infections strongly recommends the use of a CHG impregnated sponge dressing Category 1B.</td>
</tr>
<tr>
<td>SHEA/IDSA</td>
<td>Five leading healthcare stakeholders (SHEA, IDSA, AHA, APIC, and Joint Commission) have worked together to develop strategies to prevent six of the most important healthcare associated infections (HAIs), including central line associated bloodstream infections.</td>
</tr>
<tr>
<td>APIC</td>
<td>&quot;Targeting Zero&quot; Initiative - &quot;While not all infections are preventable, working toward zero should be the goal.&quot;</td>
</tr>
</tbody>
</table>
Patients need to be protected from their own skin’s microflora

Prepping the skin is not enough – 60% of CRBSI originate from the patient’s own skin!

Without continual suppression, bacteria on the skin surface can REPOPULATE and migrate into the bloodstream, elevating the risk of CRBSI.

60% from patient’s skin microflora
40% from other sources

BIOPATCH® delivers the right dose of CHG

Through its proprietary delivery technology, BIOPATCH® provides proven sustained antimicrobial action over 7 days

Within hours of thorough antiseptic application, resident bacteria quickly re-colonize the skin surface

Post-Prep (immediately following antiseptic application)
Prepping the skin reduces colony counts of bacteria from the surface only — it never completely disinfects the skin.

Post-Prep (within 1-2 days following antiseptic application)
Resident bacteria begin to re-colonize the skin surface.

Within hours of thorough antiseptic application, resident bacteria quickly re-colonize the skin surface

BIOPATCH® Protective Disk with CHG

Without BIOPATCH® Protective Disk with CHG, the skin surface quickly returns to the pre-prep environment.3

With BIOPATCH® Disk, post-prep environment extends for up to 7 days.4

Patient Risk of Infection:
Low       Medium       High

Post-Prep Day 1 – Day 2
Days 3 – 7: Return to the pre-prep environment

Pre-Prep
BIOPATCH® extends the post-prep environment for up to 7 days.

Pre-Prep
Bacteria colonies exist not only on the surface, but below the surface as well, particularly within the hair follicles and sebaceous glands.

Post-Prep
Bacteria colonize exist not only on the surface, but below the surface as well, particularly within the hair follicles and sebaceous glands.
BIOPATCH® delivers the right dose of CHG

Through its proprietary delivery technology, BIOPATCH® provides proven sustained antimicrobial action over 7 days

Extended release technology.

BIOPATCH® continuously delivers CHG over 7 days to maintain skin antisepsis:

- Specifically engineered urethane composite material is designed to continuously release CHG – not duplicated by other dressings
- The presence of moisture in the patient’s skin initiates the quick release of CHG to maintain the post-prep environment and ongoing skin antisepsis
- Reduces bacteria levels on patients
- Absorbs 8 times its own weight in fluids
- Eliminates frequent dressing changes reducing opportunity to spread bacteria by direct contact
- Ability to see site has been shown to be an unreliable predictor of CRBSIs
- BIOPATCH® is the ONLY protective disk with CHG PROVEN in multiple Randomized Control Trials to reduce the incidence of CRBSIs

Use with both vascular and nonvascular percutaneous devices

Peripheral IVs
Drains
Central Venous Catheters
Dialysis Catheters
Arterial Catheters
PICC Lines
Mid Lines
Epidural Catheters
Implanted Venous Ports
External Fixator Pins
Dressings
Prepping the skin is not enough – 60% of CRBSI originate from the patient’s own skin.

BIOPATCH® continuously delivers CHG over 7 days to maintain skin antisepsis.

The presence of moisture in the patient’s skin initiates the quick release of CHG to maintain the post-prep environment.

Specifically engineered urethane composite material is designed to continuously release CHG – not duplicated by other dressings.

The presence of moisture in the patient’s skin initiates the quick release of CHG to maintain the post-prep environment.


BIOPATCH® is the only device of its kind with an FDA-cleared indication to reduce local infections, catheter-related bloodstream infections (CRBSIs), and skin colonization of microorganisms commonly related to CRBSIs in patients with central venous or arterial catheters.

SHEA/IDSA Practice Recommendation

In the SHEA/IDSA practice recommendations and 2011 CDC Guidelines a “chlorhexidine-containing sponge dressing” has received a Category 1B recommendation and the highest possible rating for the Quality of Evidence. Over the past 15 years BIOPATCH® has extensive clinical experience – over 15 years.
• The ONLY protective disk with CHG PROVEN to reduce CRBSIs 60%1

• Engineered for continuous protection – up to 7 days

• Powerful protection that could reduce deaths attributable to CRBSIs 13

• Contains CHG – a potent antibacterial and antifungal agent recommended by the CDC for ongoing skin antisepsis 10

• 15 years of clinical experience

<table>
<thead>
<tr>
<th>CHG CONCENTRATION</th>
<th>0106</th>
<th>4151</th>
<th>4152</th>
</tr>
</thead>
<tbody>
<tr>
<td>0106 mg</td>
<td>0.15%</td>
<td>0.25%</td>
<td>0.5%</td>
</tr>
</tbody>
</table>

| DRESSING | 52 mg | 52.9 mg | 86.8 mg |

<table>
<thead>
<tr>
<th>QUANTITY PER CASE</th>
<th>10/box</th>
<th>10/box</th>
<th>10/box</th>
</tr>
</thead>
<tbody>
<tr>
<td>92 mg</td>
<td>52.5 mg</td>
<td>86.8 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SIZE RANGE</th>
<th>1” disk (2.5 cm)</th>
<th>3/4” disk (1.9 cm)</th>
<th>1” disk (2.5 cm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CENTER HOLE</td>
<td>w/4.0 mm</td>
<td>w/1.5 mm</td>
<td>w/7.0 mm</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SIZE RANGE</th>
<th>6-12 Fr</th>
<th>&lt;6 Fr</th>
<th>13-20 Fr</th>
</tr>
</thead>
</table>

| AMOUNT OF CHG PER DRESSING | 92 mg | 52.5 mg | 86.8 mg |

<table>
<thead>
<tr>
<th>QUANTITY PER CASE</th>
<th>10/box</th>
<th>10/box</th>
<th>10/box</th>
</tr>
</thead>
<tbody>
<tr>
<td>AVERAGE AMOUNT OF CHG PER DRESSING</td>
<td>92 mg</td>
<td>52.5 mg</td>
<td>86.8 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS CODE</th>
<th>11,12</th>
</tr>
</thead>
</table>

For Full Prescribing Information or Technical support, call 1-877-ETHICON (1-877-384-4266) or visit www.BIOPATCH.com

To place an order, call 1-800-255-2500

©Ethicon, Inc. 2013   002834-130916

*WARNING: Not for use on premature infants or patients with known sensitivity to CHG. Safety and effectiveness in children under 16 years of age has not been established.

References


8. BIOPATCH® Protective Disk with CHG (Full Prescribing Information). Somerville, NJ. ETHICON, Inc.


12. The information contained in this document is provided for informational purposes only and represents no statement, promise, or guarantee by Johnson & Johnson Wound Management concerning levels of reimbursement, payment, or charge. Similarly, all CPT (copyright AMA) and HCPCS codes are supplied for informational purposes only and represent no statement, promise, or guarantee by Johnson & Johnson Wound Management that these codes will be appropriate or that reimbursement will be made. It is not intended to increase or maximize reimbursement by any payor. We strongly recommend that you consult your payor organization with regard to its reimbursement policies.